Dracorhodin
Based on 2 publication(s) in Google Scholar
Dracorhodin is a natural product that can be obtained from the natural active molecule Dragon's blood. Dracorhodin inhibits PI3K/Akt and NF-κB activation, upregulates p53 expression, activates caspase, produces ROS, and promotes Apoptosis. Dracorhodin regulates the TLR4. Dracorhodin promotes wound healing, improves diabetes. Dracorhodin has anti-tumor activity against prostate cancer, breast cancer, cervical cancer and other cancers.
For research use only. We do not sell to patients.
- Purity : 96.76%
- CAS No.: 643-56-1
- Formula: C17H14O3
- Molecular Weight:266.29
-
Storage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Dracorhodin
MoreAll Caspase Isoforms
More
Biological Activity
Description
|
TLR4 |
Caspase 3 |
In Vitro
Dracorhodin (0-80 μM; 12-48 h) inhibits the growth of human cervical cancer HeLa cells, human malignant melanoma A375-S2 cells, human breast cancer MCF-7 cells and human histiocytic lymphoma U937 cells in a dose-and time-dependent manner[1].
Dracorhodin (0-200 μM; 48 h) inhibits the growth of human gastric adenocarcinoma SGC-7901 cells in a dose-dependent manner[2].
Dracorhodin (0.625-40 μg/mL; 24 h) promotes the proliferation of NIH/3T3 fibroblasts at concentrations of 0.625-10 μg/mL and inhibits proliferation at concentrations >20 μg/mL[3].
Dracorhodin (10-80 μM；12-48 h) inhibits the growth of human prostate cancer PC-3 cells in a dose-and time-dependent manner, with an IC50 of 40.18 μM at 24 h[4].
Dracorhodin (40-150 μM; 12-48 h) inhibits the growth of MCF-7 cells in a dose-and time-dependent manner[5].
Dracorhodin (10 μg/mL; 3-9 h) upregulates Pdx1 expression in INS-1 cells[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Dracorhodin (200 μg/mL; topical application) promotes skin wound healing, collagen deposition, and microvascular formation in diabetic rats by regulating the TLR4 pathway and related inflammatory factors[6].
Dracorhodin (5-20 mg/kg; i.p.; every other day; 30 d) lowers blood glucose, raises insulin levels, enhances Pdx1 expression, increases islet size and number, and shows protective effects on islets and β-cells in diabetic mice[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
- RNA extraction experimental
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Annexin V plus membrane-impermeant dye apoptosis staining
- ROS/oxidative-stress fluorescent staining
- Cell migration
- Apoptosis Solutions
- Research Protocol for Inflammation-related Diseases
- Cell-Exclusion Zone Migration Assay
- Research Protocol for Metabolic Diseases
- Breast Cancer Modeling
Chemical Information
-
CAS No. 643-56-1
-
Appearance Solid
-
Molecular Weight 266.29
-
Formula C17H14O3
-
Color Brown to reddish brown
-
SMILES
O=C(C(C)=C1OC)C=C2C1=CC=C(C3=CC=CC=C3)O2
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Int Immunopharmacol
Dracorhodin perochlorate sensitizes colorectal cancer to ferroptosis by activating HMOX1 and inhibiting the SLC7A11/GPX4 axis. [Abstract]2025 Jun 17:158:114827. PMID: 40359890 -
Solvent & Solubility
In Vitro:
DMSO : 10.6516 mg/mL (40.00 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
DMSO : 5 mg/mL (18.78 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (291 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Rasul A, et al. Dracorhodin perchlorate inhibits PI3K/Akt and NF-κB activation, up-regulates the expression of p53, and enhances apoptosis. Apoptosis. 2012 Oct;17(10):1104-19. [Content Brief]
[2]. Xia M, et al. Dracorhodin perchlorate induces apoptosis via activation of caspases and generation of reactive oxygen species. J Pharmacol Sci. 2004 Jun;95(2):273-83. [Content Brief]
[3]. Jiang X, et al. Dracorhodin perchlorate regulates fibroblast proliferation to promote rat's wound healing. J Pharmacol Sci. 2018 Feb;136(2):66-72. [Content Brief]
[4]. He Y, et al. Dracorhodin perchlorate suppresses proliferation and induces apoptosis in human prostate cancer cell line PC-3. J Huazhong Univ Sci Technolog Med Sci. 2011 Apr;31(2):215. [Content Brief]
[5]. Yu JH, et al. Dracorhodin perchlorate induced human breast cancer MCF-7 apoptosis through mitochondrial pathways. Int J Med Sci. 2013 Jul 7;10(9):1149-56. [Content Brief]
[6]. Xiong Z, et al. Dracorhodin Perchlorate Regulates the Expression of Inflammatory Cytokines through the TLR4 Pathway and Improves Skin Wound Healing in Diabetic Rats. Evid Based Complement Alternat Med. 2022 Apr 14;2022:9050686. [Content Brief]
[7]. Liu L, et al. Dracorhodin perchlorate protects pancreatic β-cells against glucotoxicity- or lipotoxicity-induced dysfunction and apoptosis in vitro and in vivo. FEBS J. 2019 Sep;286(18):3718-3736. [Content Brief]
[8]. Chen X, et al. Dracorhodin perchlorate induces the apoptosis of glioma cells. Oncol Rep. 2016 Apr;35(4):2364-72. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / DMSO | 1 mM | 3.7553 mL | 18.7765 mL | 37.5530 mL | 93.8826 mL |
| 5 mM | 0.7511 mL | 3.7553 mL | 7.5106 mL | 18.7765 mL | |
| 10 mM | 0.3755 mL | 1.8777 mL | 3.7553 mL | 9.3883 mL | |
| 15 mM | 0.2504 mL | 1.2518 mL | 2.5035 mL | 6.2588 mL | |
| DMSO | 20 mM | 0.1878 mL | 0.9388 mL | 1.8777 mL | 4.6941 mL |
| 25 mM | 0.1502 mL | 0.7511 mL | 1.5021 mL | 3.7553 mL | |
| 30 mM | 0.1252 mL | 0.6259 mL | 1.2518 mL | 3.1294 mL |
Dracorhodin Related Classifications
HY-N4081 Related Classifications
Powered by Bioz